Journal Article

A new comprehensive parameter combining residual C-reactive protein and neutrophil risk predicting adverse events in Chinese patients after percutaneous coronary intervention: A multi-center prospective cohort study

Liu, Meilin, Li, Xiaolan, Xie, Qiang, Zhang, Jinying, Wang, Xiaozeng, Yao, Wei, Cheng, Xiang, Yuan, Yuanfan, Han, Xuebin, Zhu, Zhengfeng, Shan, Zhilei, Xiong, Yuyan, Yu, Miao, Yu, Liuyu, Lei, Yuhua, Dou, Kefei, Long, Qi, Yuan, Haitao, Chen, Manhua, Libby, Peter, Yang, Fen, Hong, Lifeng, Yang, Jian, Han, Yaling, Xu, Jiahao, Nie, Shaofang, Yang, Keping, Hu, Liqun, Zha, Lingfeng, He, Liqun

2026

Overview

To the Editor: Coronary heart disease (CHD) continues to be a predominant cause of mortality in China even after recommended optimal management. The results of Cox regression showed an increasing risk for the four groups of patients and a significantly higher risk of MACCE for patients with persistent high RIR (HR = 1.80, 95% CI: 1.11–2.92, P = 0.016) [Supplementary Table 7, http://links.lww.com/CM9/C676]. Since the median level of NLR at 1-month was 2.4 and the 1-month NLR ≥2.4 predicted MACCE (HR = 1.55, 95% CI: 1.06–2.26, P = 0.023) [Supplementary Figure 2, http://links.lww.com/CM9/C676], we used 1-month hsCRP and NLR to categorize the participants into four groups: Funding This work was supported by grants from the Noncommunicable Chronic Diseases—National Science and Technology Major Project (No. 2025ZD0548400), the National Key Research and Development Program (No. 2022YFC2503501), Chinese Society of Cardiology’s Foundation (No. Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics.

• Publisher: Lippincott Williams & Wilkins,Lippincott Williams & Wilkins Ovid Technologies,Wolters Kluwer Health,Wolters Kluwer
• Subject: Angioplasty / Biomarkers / C-reactive protein / Cardiology / Chronic illnesses / Cohort analysis / Correspondence / Hospitals / Medical research / Neutrophils / Pharmaceuticals / R&D / Research & development